Successful rechallenge with pembrolizumab after case of progressive immunotherapy-related mucocutaneous eruption (PIRME), a Stevens-Johnson syndrome-like reaction.
暂无分享，去创建一个
K. Reynolds | J. Clark | M. Shaughnessy | C. Shi | S.T. Chen | K. Sehgal | J. Toyohara
[1] J. Sosman,et al. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.
[2] Li Zhang,et al. Immune checkpoint inhibitor-related epidermal necrolysis: A rare condition with poor prognosis. , 2021, European journal of cancer.
[3] K. Reynolds,et al. Generalized Bullous Mucocutaneous Eruption Mimicking Stevens-Johnson Syndrome in the Setting of Immune Checkpoint Inhibition: A Multicenter Case Series. , 2020, Journal of the American Academy of Dermatology.
[4] Daniel Q. Bach,et al. Stevens‐Johnson syndrome and toxic epidermal necrolysis‐like reactions to checkpoint inhibitors: a systematic review , 2020, International journal of dermatology.